Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction
Source: SeekingAlpha
2025-11-26 15:19:25 ET
More on Otsuka
- Sanofi, Lilly among winners of EU drug recommendations this week
- Trump’s 100% drug tariffs send pharma stocks lower
- Seeking Alpha’s Quant Rating on Otsuka Holdings
- Historical earnings data for Otsuka Holdings
- Dividend scorecard for Otsuka Holdings
Read the full article on Seeking Alpha
For further details see:
Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction
Otsuka Holdings Co. Ltd.
NASDAQ: OTSKF
OTSKF Trading
0.0% G/L:
$67.105 Last:
107 Volume:
$67.105 Open:
OTSKF Latest News
May 17, 2025 01:00:00 am
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
February 06, 2025 02:00:00 pm
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
